Intervertebral disc regeneration: From cell therapy to the development of novel bioinspired endogenous repair strategies

Adv Drug Deliv Rev. 2019 Jun:146:306-324. doi: 10.1016/j.addr.2018.04.017. Epub 2018 Apr 26.

Abstract

Low back pain (LBP), frequently associated with intervertebral disc (IVD) degeneration, is a major public health concern. LBP is currently managed by pharmacological treatments and, if unsuccessful, by invasive surgical procedures, which do not counteract the degenerative process. Considering that IVD cell depletion is critical in the degenerative process, the supplementation of IVD with reparative cells, associated or not with biomaterials, has been contemplated. Recently, the discovery of reparative stem/progenitor cells in the IVD has led to increased interest in the potential of endogenous repair strategies. Recruitment of these cells by specific signals might constitute an alternative strategy to cell transplantation. Here, we review the status of cell-based therapies for treating IVD degeneration and emphasize the current concept of endogenous repair as well as future perspectives. This review also highlights the challenges of the mobilization/differentiation of reparative progenitor cells through the delivery of biologics factors to stimulate IVD regeneration.

Keywords: Biomaterials, chemokines; Disc degenerative disease; Drug delivery systems; Growth factors; Low back pain; Progenitor cells; Regenerative medicine; Stem cells; miRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy*
  • Humans
  • Intervertebral Disc Degeneration* / metabolism
  • Intervertebral Disc Degeneration* / therapy
  • Mesenchymal Stem Cell Transplantation*
  • Regeneration*